PhysioGenix Inc.
This article was originally published in Start Up
Executive Summary
PhysioGenix wants to reduce drug failure rates in clinical trials with multigenic rat models that can be used in parallel for target validation, drug screening, and predictive toxicology. The company is providing animal models and services related to therapeutic proof-of-concept and predictive toxicology to help pharma clients accelerate their product development processes. Over time, PhysioGenix expects to provide these services in concert with internal early drug development programs.
You may also be interested in...
Start-Ups with Predictive ADME/Tox Technologies
Ask a head of R&D for a pharma or biotech to name the area where the need for new and better tools is greatest, and likely as not the answer will be predictive modeling of a drug's ADME/Tox profile. There's an abundance of sweet spots across the preclinical landscape for companies with better models and predictive tools.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.